Marsh & McLennan has cleared its Q2 earnings hurdle, but the analyst response to the print has opened a fresh divide on the stock — with one major firm stepping back just as bulls raise their targets.
The most notable post-earnings move came from Citigroup, which downgraded MRSH to Neutral from Buy on July 22, holding its $200 target unchanged. That retreat lands on the same day Mizuho lifted its own target to $201 from $197, also at Neutral. The two actions capture the Street's split personality on this name. JP Morgan, Cantor Fitzgerald, and UBS remain in the bull camp — with targets at $212, $218, and $212 respectively — while Morgan Stanley earlier trimmed to $175, an Equal-Weight that sits below the current price of $181.59. The consensus mean target of $201.90 implies roughly 11% upside, but the distribution of views is wide: the range spans from Morgan Stanley's $175 floor to Evercore ISI's $234 ceiling. The stock has gained nearly 12% over the past month. That run has compressed the easy upside the bulls were pointing to before earnings, which may explain why Citi chose this moment to step back.
Options positioning has eased materially since the pre-earnings anxiety flagged in prior notes. The put/call ratio now reads 0.71 — still about 1.4 standard deviations above its 20-day mean of 0.56, and clearly elevated compared to the sub-0.50 readings that prevailed through June. But this is a meaningful improvement from the near-three-standard-deviation spike on July 10, when hedging pressure was at its most acute. The borrow market adds almost nothing to the story: short interest has fallen 7% over the past week to just 1.3% of free float, borrowing costs are a negligible 0.37%, and availability is essentially unconstrained. There is no squeeze pressure here, and no sign that short sellers are rebuilding after the earnings release.
The factor picture is mixed but not alarming. The dividend score ranks in the 88th percentile — a genuine standout, though the dividend data in the snapshot is stale and should be treated as directional only. The short score of 30.4 has drifted lower through July, consistent with the declining short interest. The ORTEX short score rank sits at the 71st percentile, meaning the stock looks less shorted than the majority of its universe. PE has expanded to roughly 16.6x on a trailing basis, up about 1.8 turns over the past month — a reflection of the price rally rather than an earnings beat driving multiple compression. EV/EBITDA has edged slightly lower over the same period, now near 12.6x.
The peer group has had a tougher week. AJG fell 2.2% and BRO dropped 2.7%, while ERIE shed 9.5% — the weakest reading in the group. AON was close to flat on the week at +0.1%, and WTW similarly unchanged. Against that backdrop, MMC's 2% weekly gain looks relatively constructive, though the stock slipped 0.3% on July 21 — the day of the earnings release itself — suggesting the print was largely priced in after the month-long run.
The question now is whether the Citi downgrade marks the start of a broader reassessment, or whether it is an isolated post-earnings housekeeping move from a firm that had been too constructive heading into a richly priced quarter. With no next earnings date yet confirmed, the near-term focus shifts to whether remaining bulls maintain conviction as the stock digests at current levels.
See the live data behind this article on ORTEX.
Open MRSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
